The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.

Cigna Group closed $14.69 short of its 52-week high ($370.83), which the company reached on September 16th.

The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive ...

The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies ...

The Federal Trade Commission (FTC) is suing pharmacy benefit managers CVS Health (CVS), Cigna Group (CI), and UnitedHealth ...

Bloomberg Washington Correspondents Joe Mathieu and Kailey Leinz deliver insight and analysis on the latest headlines from ...

The Federal Trade Commission has accused three major pharmacy benefit managers of inflating insulin prices, the agency said ...

On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers ...

The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged ...

The Federal Trade Commission filed an action against the three largest prescription drug benefit managers or PBMs— CVS Health's ...

The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in ...

The FTC sued UnitedHealth Group’s Optum unit, CVS Caremark and Cigna’s Express Scripts for allegedly steering diabetes ...